Protection of neurons in vitro and in vivo from Synuclein toxicity by molecular tweezers

Lead Research Organisation: University of Oxford
Department Name: Physiology Anatomy and Genetics

Abstract

Parkinson's disease is an age-related neurodegenerative disorder in which aggregated clumps of a protein termed alpha-synuclein form in neurons, the cells in the brain which relay electrical information. These clumps are the defining key hallmark pathology of Parkinson's and are called Lewy bodies (LB). In a related disease, multiple system atrophy (MSA), the protein clumps form in the support cells, called glia. The diseases are therefore related and may benefit from a therapy to prevent the formation and spread of alpha-synuclein protein clumps.

The development of therapeutic strategies to prevent the formation and spread of alpha-synuclein protein clumps and prevent cell death in Parkinson's and MSA has been limited by a lack of understanding of the mechanisms driving neurodegeneration. However, increasing evidence demonstrates the importance of the alpha-synuclein clumps in disease pathology and has led to consider the therapeutic potential of several strategies aimed at reducing the burden and toxicity of alpha-synuclein accumulation. Our objective here is to build upon the unique experimental models of disease and complementary expertise of the Consortium. Members of the research team specialise in working in brain cells from mice, and with human neurons derived from stem cells made from Parkinson's patients. Others members of the team work on animal models of Parkinson's and MSA which model how alpha-synuclein may spread in the brain. We will use these models in laboratories in France and in the UK to test a novel molecular therapy called "molecular tweezer" drug which has been shown to inhibit aggregation and toxicity of other similar proteins which clump in other diseases. The drug may therefore protect neurons grown in the laboratory and neurons in the brain from Parkinson's or MSA-associated cell death. By probing the mechanisms and application of "molecular tweezers" to Parkinson's and MSA the project will demonstrate the use or not of such a therapy to prevent alpha-synuclein-mediated cell death.

Technical Summary

Parkinson disease (PD) is hallmarked by the deposition of aggregated alpha-synuclein (alpha-syn) species into intra-neuronal Lewy bodies (LB) and Lewy neurites (LN) inclusions while in multiple system atrophy (MSA) alpha-syn aggregates form oligodendroglial inclusions. The development of therapeutic strategies to block cell death in PD and MSA has been limited by a lack of understanding of the mechanisms driving neurodegeneration. However, increasing evidence of multiple pivotal roles of alpha-syn in the pathogenesis of PD and MSA has led to consider the therapeutic potential of several strategies aimed at reducing alpha-synuclein toxicity. Our objective is to build upon the unique experimental cell (Primary rodent neurons and glial cells - Human neurons derived from PD patients) and animal models of PD (SNCAOVX transgenic mouse and human PD-derived alpha-syn seed-injected mouse) and MSA (PLP-SYN transgenic mouse and human MSA-derived alpha-syn seed-injected mouse), developed by this consortium, for testing whether the prototypical molecular tweezer CLR01, shown to inhibit aggregation and toxicity of other amyloidogenic proteins, could protect neurons in vitro and in vivo from PD / MSA-associated synaptotoxicity and reduce PD and MSA's disease-like alpha-syn pathology. The project will thus (in)validate the molecular tweezers CLR01 for PD and/or MSA indications.

Planned Impact

The project will foster the development of disease-modifying treatment. To this end, it will develop and characterize a novel innovative molecule (CLR01) in clinically relevant human patient-derived dopaminergic neurons and in novel animal models to study its ability to interfere with alpha-syn pathology that it is induced by increased expression or by pathophysiological spread of patient-derived alpha-syn assemblies.

The synergy between the three complementary laboratories will maximize the potential for achieving these goals. We will efficiently share and transfer key materials, protocols and data between our laboratories, raising the chances of yielding synergistic, interdisciplinary, and groundbreaking research results. Hence, the outcome will be more than the arithmetic sum of each of our respective expertise, working force and the respective local academic environments. The multidisciplinary aspect of the project is essential to its objectives. It will benefit from expertise in many disciplines within neuroscience, delineating a clear synergistic network of competencies. Not only are different complementary capabilities needed to succeed, but a truly synergistic framework is mandatory. Our newly established links will allow implementing an innovative way of synergic work. The immediate potential impact on both academic and industrial research domains aiming at developing neuroprotective treatments justifies accepting this challenge, as success of this grant would increase Europe competitiveness in an area of neuroscience and neurology which is under high demand and expectation for newer and more efficacious therapeutic approaches.

Publications

10 25 50
 
Description Inhibition of alpha-synuclein aggregation and glial activation as a therapeutic strategy for Parkinson's disease
Amount £500,000 (GBP)
Organisation Bristol-Myers Squibb 
Department Celgene
Sector Private
Country United States
Start 03/2018 
End 03/2021
 
Description SRUK winter studentship
Amount € 2,400 (EUR)
Organisation Society of Spanish Researchers in the United Kingdom 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Title Dopamine neuron microfluidics 
Description Development of stem cell-derived neuronal culture techniques using microfluidic devices to channel axonal growth. 
Type Of Material Model of mechanisms or symptoms - in vitro 
Provided To Others? No  
Impact Not yet: it is ongoing development 
 
Title Osmotic mini-pump implantation 
Description We have optimised the methodology for delivery of the potential therapeutic CLR01 in vivo usoing osmotic mini-pumps. 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Provided To Others? No  
Impact Pilot data suggest that CLR01 in vivo may reduce a-syn oligomer burden 
 
Title PLA in stem cell neurons 
Description To enable the detection of a-syn oligomers in stem cell-derived dopamine neurons 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? Yes  
Impact The detection of a-syn oligomers in stem cell-derived dopamine neurons 
 
Description COEN Group on Parkinson's 
Organisation University of Bordeaux
Country France 
Sector Academic/University 
PI Contribution We have contributed Parkinson's derived patient-derived stem cells and neurons. We have then used materials and expertise provided by other partners in our patient neuron cultures.
Collaborator Contribution The University of the Basque Country has provided expertise on advanced microfluidics cell culture. Bordeaux has provided brain extract from Parkinson's patients and the potential therapic compound CLR01.
Impact No outputs yet as collaboration is still new.
Start Year 2016
 
Description COEN Group on Parkinson's 
Organisation University of the Basque Country
Country Spain 
Sector Academic/University 
PI Contribution We have contributed Parkinson's derived patient-derived stem cells and neurons. We have then used materials and expertise provided by other partners in our patient neuron cultures.
Collaborator Contribution The University of the Basque Country has provided expertise on advanced microfluidics cell culture. Bordeaux has provided brain extract from Parkinson's patients and the potential therapic compound CLR01.
Impact No outputs yet as collaboration is still new.
Start Year 2016
 
Description Microfluidics and proximity ligation assay research 
Organisation Achucarro Basque Center for Neuroscience
Department Laboratory of Neurobiology
Country Spain 
Sector Academic/University 
PI Contribution Nora Bengoa-Vergniory shared her expertise on alpha-synuclein proximity ligation assays
Collaborator Contribution Fabio Cavaliere and Paula Ramos shared knowledge of microfludics
Impact Ongoing research in both institutes
Start Year 2017
 
Description ARUK/BRC Oxford Dementia Research Day 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact a day of talks celebrating the exciting research in the region including updates on some of the exciting big dementia research initiatives such as the ARUK Oxford Drug Discovery Institute, Dementia Platform UK, the NIHR Oxford Health Biomedical Research Centre and the Oxford Momentum Award. Accredited for 5 CPD credits.
Year(s) Of Engagement Activity 2017
URL https://www.dpag.ox.ac.uk/research/wade-martins-group/oxford-aruk-network-centre/research-day-2015
 
Description Caution when looking at cell recycling in Parkinson's 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Supporters
Results and Impact Media press release by Parkinson's UK highlighting that researchers at the Oxford Parkinson's Disease Centre have shown that cell recycling in Parkinson's may play a more complex role than previously thought. These new results have been published in the journal of Cell Reports.
Year(s) Of Engagement Activity 2019
URL https://www.parkinsons.org.uk/news/caution-when-looking-cell-recycling-parkinsons
 
Description Downing Street 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Inivitation to attend reception at 10, Downing Street
Year(s) Of Engagement Activity 2017
 
Description Dr. Nora Bengoa-Vergniory gave a Poster tour presentation at the World Parkinson's Congress, Kyoto Japan. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Dr. Nora Bengoa-Vergniory gave a Poster tour presentation at the World Parkinson's Congress, Kyoto Japan.
Subject: CLR01 protects dopaminergic neurons in vitro and in vivo in mouse and human models
Year(s) Of Engagement Activity 2019
URL https://www.worldpdcoalition.org/page/PastCongresses
 
Description Dr. Nora Bengoa-Vergniory gave a oral presentation at the Neuroscience symposium, Oxford UK (2019). 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Dr. Nora Bengoa-Vergniory gave a oral presentation at the Neuroscience symposium, Oxford UK (2019).
Year(s) Of Engagement Activity 2019
 
Description Dr. Nora Bengoa-Vergniory gave an oral presentation at the Parkinson's Disease Gordon Research Conference Seminar, Maine USA 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Dr. Nora Bengoa-Vergniory gave an oral presentation at the Parkinson's Disease Gordon Research Conference Seminar, Maine USA June 23 - 28, 2019
Subject: CLR01 protects dopaminergic neurons in vitro and in vivo in mouse and human models
Year(s) Of Engagement Activity 2019
URL https://www.grc.org/parkinson-s-disease-conference/2019/
 
Description Gordon Research Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Nora Bengoa-Vergniory "Mass-spectrometry approach highlights REST as a potential neuroprotective target for Parkinson's disease in an alpha synuclein overexpressing BAC-transgenic mouse model" Oral presentation Posters: Nora Bengoa-Vergniory, Dayne Beccano-Kelly, Natalie Connor-Robson, Rebecca Wallings
Year(s) Of Engagement Activity 2017
URL https://www.grc.org/parkinson-s-disease-conference/2017/
 
Description Invited to talk at the ARUK Dementia Research Day - Dr. Nora Bengoa-Vergniory 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact On 31July 2019, was invited to talk at the ARUK Dementia Research Day.
Subject: CLR01 protects dopaminergic neurons in vitro and in vivo in mouse and human models
Year(s) Of Engagement Activity 2019
 
Description Neurogune talks, Bilbao Spain 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact "Alpha-synuclein overexpressing mice and protection of neurons from synuclein toxicity by molecular tweezers" Oral presentation Nora Bengoa-Vergniory
Year(s) Of Engagement Activity 2017
 
Description News story and video featuring the Wade-Martins lab to mark World Parkinson's Day 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact News story to mark World Parkinson's Day, featuring a video with an inside look into the Wade-Martins Laboratory.

The Wade-Martins Group conducts critical research into several neurodegenerative diseases, and makes up part of the OPDC with its work into Parkinson's, with the aim to understand the molecular mechanisms of these disorders and help develop new treatments.

This video is narrated by Professor Richard Wade-Martins, with contributions from Charmaine Lang, Dayne Beccano-Kelly, Peter Kilfeather, Phillippa Carling, Gabriela Vilema Enriquez and former members of the team, Gabriele Corda, Rebecca Wallings and Marta Cherubini.
Year(s) Of Engagement Activity 2019
URL https://www.opdc.ox.ac.uk/inside-the-wade-martins-lab
 
Description News story and video highlighting an OPDC study that has uncovered a new way to target and treat the leading genetic contributor to Parkinson's 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Supporters
Results and Impact News story featuring a research paper that has identified how the dysfunction of a key protein, LRRK2, causes the neurons affected in Parkinson's to lose their ability to effectively clear out cell components that have been damaged. This discovery has enabled the team to find a new way to target and correct this issue, paving the way for a potential new clinical treatment.
Year(s) Of Engagement Activity 2019
URL https://www.opdc.ox.ac.uk/opdc-study-uncovers-a-new-way-to-target-and-treat-the-leading-genetic-cont...
 
Description News story featuring a new study on neurons grown from skin samples reveals key molecular changes in people with Parkinson's 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Supporters
Results and Impact News story highlighting a new research paper in Human Molecular Genetics: Cellular a-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons
Year(s) Of Engagement Activity 2019
URL https://www.opdc.ox.ac.uk/new-opdc-study-on-neurons-grown-from-skin-samples-reveals-key-molecular-ch...
 
Description News story highlighting a new paper to report genome-wide transcriptomic RNA-Seq profiling of stem cell-derived astrocytes from people with Parkinson's & healthy controls. 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The news items highlighted a new research paper that was published to report genome-wide transcriptomic RNA-Seq profiling of stem cell-derived astrocytes from people with Parkinson's & healthy controls.
Year(s) Of Engagement Activity 2019
URL https://www.opdc.ox.ac.uk/new-opdc-research-into-the-role-of-astrocytes-in-parkinson-s-progression
 
Description News story promoting that a new study finds mutations in the gene LRRK2 affect normal cell function 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Supporters
Results and Impact A new story featured on our website about a new study from OPDC Career Development Fellow Natalie Connor-Robson who has investigated how mutations in the gene LRRK2, which are known to cause Parkinson's, effect normal cell function.
Year(s) Of Engagement Activity 2019
URL https://www.opdc.ox.ac.uk/opdc-study-finds-mutations-in-the-gene-lrrk2-affect-normal-cell-function
 
Description Nora Bengoa-Vergniory article on Celgene Fellowship 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Postgraduate students
Results and Impact Interviwe with Dr Nora Bengoa-Vergniory on her experience as a Celgene Fellow for the Oxford University Medical Sciences division website
Year(s) Of Engagement Activity 2018
URL https://www.medsci.ox.ac.uk/research/internal/funding-directory/oxford-celgene-fellowship/oxford-cel...
 
Description OPDC Open Day 2016 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Study participants or study members
Results and Impact OPDC Open Day 2016
250 OPDC study Participants and Partners registered for event.
Day of talks from Michele Hu, Fahd Baig, Claudio Ruffmann, Tom Barber and Richard Wade-Martins.
Discussion of what participants would like from study.
Talks filmed and podcasts added to website
Year(s) Of Engagement Activity 2016
URL http://www.opdc.ox.ac.uk/openday2016
 
Description OPDC Research Day 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact The OPDC Research Day is a one-day event with research talks from world leading Parkinson's researchers on topics including clinical studies, imaging, genetics, proteomics, neuronal cells and animal models.
The 2017 OPDC Research Day was held in the Medical Sciences Teaching Centre, Oxford.
There was a full day of talks and poster sessions on Parkinson's research.
This one-day event included research talks by national and international keynote speakers and Oxford researchers on a range of Parkinson's work including clinical studies, imaging, genetics, proteomics, neuronal cell culture and animal models.
Year(s) Of Engagement Activity 2017
URL http://www.opdc.ox.ac.uk/research2017
 
Description Oxford PD UK 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact I spoke at a meeting of the Oxford Parkinson's UK branch
Year(s) Of Engagement Activity 2017
 
Description Oxford PD UK Carol Service and walk 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact Attended and supported Parkinson's UK Oxford Carol service and sponsored walk 2016
Year(s) Of Engagement Activity 2016
 
Description Parkinson's UK Oxford Walk 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact On 22 September, Professor Richard Wade-Martins & Dr Laura Parkinnen took part in the Parkinson's UK Oxford Walk.
Year(s) Of Engagement Activity 2019
 
Description Parkinson's UK walk 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Supporters
Results and Impact Went on a sponsored walk

Raised money and awareness
Year(s) Of Engagement Activity 2014,2015
 
Description Parkinson's public awareness talk at Green Templeton College 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact On 11 September 2019, Professor Wade-Martins gave a public awareness talk about Parkinson's Disease at Green Templeton College
Year(s) Of Engagement Activity 2019
 
Description Poster and flash talk at the International Ataxia Research Conference (AIRC) November 19 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Conference abstract, poster presentation, "A CRISPR/Cas9 genome-wide screen identify DDX6 as a novel regulator of FXN expression in Friedreich's ataxia", International Ataxia Research Conference 2019, Washington D.C, United States. Attended by Gabriela Vilema Enríquez & Professor Richard Wade-Martins
Year(s) Of Engagement Activity 2019
URL http://iarc2019.org/
 
Description Poster at Advances in Neurodegenerative Disease Research and Therapy/New Frontiers in Neuroinflammation Keystone Conference, Colorado USA 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Nora Bengoa-Vergniory poster
"Tau-proximity ligation assay detects pathology ahead of tau neurofibrillary tangles in Alzheimer's disease"

As the world population ages, neurodegenerative diseases are becoming the new epidemic in both developed and developing countries. Progress made in human genetics has revealed increasingly more disease-associated genes for Alzheimer's disease (AD), Parkinson's disease (PD), Frontotemoral dementia (FTD), amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. These discoveries have linked neurodegenerative diseases with several common key biological processes that have so far been under-studied, including RNA metabolism, protein trafficking and innate immune responses. By focusing on these emerging areas in neurodegenerative disease research, this conference seeks to challenge the current research paradigms and to inspire in-depth discussion and exploration. The program assembles leaders from various fields to facilitate interactions between groups using diverse approaches, by providing a platform to cross-fertilize ideas and to encourage new collaborations that could lead to novel mechanisms and therapeutic targets against neurodegenerative diseases.
Year(s) Of Engagement Activity 2018
URL http://www.keystonesymposia.org/18Z3
 
Description Professor Richard Wade-Martin gave a talk at the Longevity Forum at Oriel College, Oxford 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact On 12 November, Professor Richard Wade-Martin gave a talk at the Science Summit, Longevity Forum at Oriel College, Oxford
Year(s) Of Engagement Activity 2019
URL https://thelongevityforum.com/the-longevity-week/
 
Description Professor Richard Wade-Martins gave a talk at the Oxford Stem Institute Symposium 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact on 18 September, Professor Richard Wade-Martins gave a talk at the Oxford Stem Institute Symposium 2019. Stems Cell: From Mechanism to Therapy
Year(s) Of Engagement Activity 2019
URL https://www.stemcells.ox.ac.uk/home
 
Description Professor Richard Wade-Martins gave an ARUK Target Drug Discovery talk along with Dr George Tofaris 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact On 12 November, Professor Richard Wade-Martins gave an ARUK Target Drug Discovery talk along with Dr George Tofaris
Year(s) Of Engagement Activity 2019
 
Description Profile on Nora Bengoa-Vergniory and workplace 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Recorded in 2019, Dr Nora Bengoa-Vergniory was filmed over a day for a Basque TV programme called "Vascos por el mundo".
She was shown in her daily workplace inside the Wade-Martins lab.
Year(s) Of Engagement Activity 2019
URL https://www.eitb.eus/es/television/programas/vascos-por-el-mundo/
 
Description Pub quiz in aid of Parkinson's Research 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Siv Vingill, Melanie Witt, Dayne Beccano-Kelly, Nora Bengoa-Vergniory and Melanie Witt took part in pub quiz held at the Barleycorn pub near Andover raising funds for Parkinson's research in Oxford. They met with supporters and talked about their work.
Year(s) Of Engagement Activity 2018
URL https://www.opdc.ox.ac.uk/oxford-parkinson-s-disease-centre-members-raise-funds-for-their-research-a...
 
Description Pub quiz in aid of Parkinson's Research 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Richard Wade-Martins, Dayne Beccano-Kelly, Nora Bengoa-Vergniory, Marta Madureira, Brent Ryan, Matthieu Trigano, Siv Vingill, along with OPDC administrator, Lorraine Dyson, travelled to the Royal Oak, Goodworth Clatford in Andover to take part in a quiz night in aid of Parkinson's research.

They met with supporters and talked about their work. OPDC supporters Bobbie Coelho, Mary Doherty and Dawn Huntly presented a cheque for £2000 to Professor Richard Wade-Martins to support the work being carried out by the OPDC into Parkinson's Disease.
Year(s) Of Engagement Activity 2019
URL https://www.opdc.ox.ac.uk/oxford-parkinson-s-disease-centre-support-charity-christmas-pub-quiz
 
Description Talk at the Biomedical Research Foundation Academy of Athens, Greece March 2020 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Professor Richard Wade Martins gave a talk at the Biomedical Research Foundation Academy of Athens, Greece in March 2020
Year(s) Of Engagement Activity 2020
URL http://www.bioacademy.gr/about
 
Description Talk at the HOPE Conference for Parkinson's Research, Paris Jan 2020 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Professor Richard Wade-Martins gave a talk at the HOPE Conference for Parkinson's Research, Paris 29-31 Jan 2020
Year(s) Of Engagement Activity 2020
URL https://hope2020.sciencesconf.org/
 
Description Talk at the University College London, IoN Movement Disorders Centre Inaugural Symposium: 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact On 11 March, Professor Richard Wade-Martins gave a talk at the University College London, IoN Movement Disorders Centre Inaugural Symposium: Launch of the UCL Movement Disorders Centre
Year(s) Of Engagement Activity 2020
URL http://www.ucl.ac.uk/ion/events/2020/mar/ucl-ion-movement-disorders-centre-inaugural-symposium-launc...